Xenon's Phase 3 Supports A 'Buy' Despite Its Premium (NASDAQ:XENE)
Summary
Xenon Pharmaceuticals’ bull case improved after X-TOLE2 showed robust focal seizure reduction in a highly refractory patient population. For more on XENE stoc...
Description
Xenon Pharmaceuticals’ bull case improved after X-TOLE2 showed robust focal seizure reduction in a highly refractory patient population. For more on XENE stoc...
Original reporting
AFBytes is a read-only aggregator. Use the original source for full context and complete reporting.
Open original source